Genome-wide association study of copy number variations in Parkinson's disease.
A large CNV GWAS in 10,815 PD cases and 8,901 controls identified and replicated exon 2–6 deletions in PRKN as enriched in early-onset PD and associated with earlier age at onset.
What the AI sees
A large CNV GWAS in 10,815 PD cases and 8,901 controls identified and replicated exon 2–6 deletions in PRKN as enriched in early-onset PD and associated with earlier age at onset.
Research significance
Confirms PRKN deletions as a clinically actionable genetic driver in early-onset PD, informing genetic testing, patient stratification for trials, and development of Parkin-targeted therapeutic approaches.
Source abstract
We investigated the role of copy number variations (CNVs) in Parkinson's disease (PD) using genotyping data from 10,815 patients (2731 early-onset PD, EOPD) and 8901 controls from the COURAGE-PD consortium. CNVs were analyzed using a sliding window genome-wide association and burden approach. No genome-wide significant CNVs were detected in the overall cohort, but a robust deletion spanning exons 2-6 of PRKN was identified in EOPD cases, validated by MLPA, and replicated in the GP2 dataset (23,089 cases, 18,824 controls). CNV burden was significantly enriched in PD-related genes, primarily driven by PRKN, with the strongest effect observed in EOPD. PRKN CNV carriers showed earlier age at onset, confirmed by survival analysis. No association was observed for genome-wide or large CNV burden. Our findings reinforce the pivotal role of PRKN deletions in early-onset PD and highlight the need for high-resolution CNV analysis in large cohorts to uncover additional rare contributors to PD risk.